相似文献
1
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.
J Oncol. 2009;2009:581939. doi: 10.1155/2009/581939. Epub 2010 Jan 17.
2
Autoantibodies to tumor-associated antigens in breast carcinoma.
J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21.
3
Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma.
J Oncol. 2011;2011:982425. doi: 10.1155/2011/982425. Epub 2011 Mar 3.
4
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
5
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Cancer Res. 2003 Sep 15;63(18):6076-83.
6
Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer.
Cancer Biomark. 2017;18(2):105-116. doi: 10.3233/CBM-160117.
7
NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
Int J Cancer. 2005 Jul 20;115(6):960-6. doi: 10.1002/ijc.20953.
8
Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Clin Respir J. 2018 Jun;12(6):2020-2028. doi: 10.1111/crj.12769. Epub 2018 Feb 15.
9
[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
Zhonghua Bing Li Xue Za Zhi. 2005 Apr;34(4):202-5.
10
Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.
Proteomics Clin Appl. 2016 May;10(5):564-73. doi: 10.1002/prca.201500138.
引用本文的文献
1
Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
J Cancer Res Clin Oncol. 2019 Feb;145(2):281-291. doi: 10.1007/s00432-019-02840-3. Epub 2019 Jan 17.
2
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.
Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.
3
Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
PLoS One. 2015 Oct 9;10(10):e0140351. doi: 10.1371/journal.pone.0140351. eCollection 2015.
4
Plasma immune analytes in patients with epithelial ovarian cancer.
Cytokine. 2015 May;73(1):108-13. doi: 10.1016/j.cyto.2015.01.035. Epub 2015 Mar 3.
5
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.
MAbs. 2014;6(6):1608-20. doi: 10.4161/mabs.36292.
6
Autoantibody signature for the serologic detection of ovarian cancer.
J Proteome Res. 2015 Jan 2;14(1):578-86. doi: 10.1021/pr500908n. Epub 2014 Nov 17.
7
Serum autoantibody measurement for the detection of hepatocellular carcinoma.
PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.
8
The immunomodulating roles of glycoproteins in epithelial ovarian cancer.
Front Biosci (Elite Ed). 2012 Jan 1;4(2):631-50. doi: 10.2741/405.
9
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.
PLoS One. 2011;6(8):e23651. doi: 10.1371/journal.pone.0023651. Epub 2011 Aug 12.
10
Comparison of candidate serologic markers for type I and type II ovarian cancer.
Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.
本文引用的文献
1
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Gynecol Oncol. 2009 Oct;115(1):112-120. doi: 10.1016/j.ygyno.2009.06.031. Epub 2009 Jul 31.
2
HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study.
Int J Cancer. 2009 Nov 1;125(9):2214-8. doi: 10.1002/ijc.24599.
3
p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Gynecol Oncol. 2009 Jul;114(1):12-7. doi: 10.1016/j.ygyno.2009.03.028. Epub 2009 Apr 26.
4
Ovarian cancer.
Annu Rev Pathol. 2009;4:287-313. doi: 10.1146/annurev.pathol.4.110807.092246.
5
Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary.
BMC Cancer. 2008 Aug 24;8:247. doi: 10.1186/1471-2407-8-247.
6
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.
Gynecol Oncol. 2008 Nov;111(2):226-32. doi: 10.1016/j.ygyno.2008.07.018. Epub 2008 Aug 21.
7
Autoantibodies as potential biomarkers for breast cancer.
Breast Cancer Res. 2008;10(3):R40. doi: 10.1186/bcr2091. Epub 2008 May 7.
8
Cathepsin D--many functions of one aspartic protease.
Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28. doi: 10.1016/j.critrevonc.2008.02.008. Epub 2008 Apr 8.
9
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.
Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005.
10
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
Gynecol Oncol. 2008 May;109(2):168-73. doi: 10.1016/j.ygyno.2008.01.012. Epub 2008 Mar 14.
Zotero 插件